OOIR: Observatory of International Research

Papers

(The H4-Index of Pharmacotherapy is 22. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Safety and efficacy of cefiderocol for off‐label treatment indications: A systematic review	106
Acid‐suppressive drugs: A systematic review and network meta‐analysis of their nocturnal acid‐inhibitory effect	102
Warfarin dosage in a postpartum woman while breastfeeding: A case report	76
Update and narrative review of avian influenza (H5N1) infection in adult patients	62
Hydroxyurea treatment for sickle cell anemia during pregnancy and lactation: Current evidence and knowledge gaps	56
Empiric dosing strategies to predict lamotrigine concentrations during pregnancy	49
	42
Assessment and management of iatrogenic withdrawal syndrome and delirium in pediatric intensive care units across Europe: An ESPNIC survey	40
Characterization of lamotrigine disposition changes during and after pregnancy in women with epilepsy	39
A Multicenter, Open‐Label Study to Assess the Safety of Nebulized Tissue Plasminogen Activator for the Acute Treatment of Pediatric Plastic Bronchitis: The PLATyPuS Trial	35
Changes in serum potassium in people with type 2 diabetes taking sodium‐glucose co‐transporter‐2 inhibitors	35
Comparative safety and efficacy of bisphosphonates, denosumab, and parathyroid hormone analogs for osteoporosis following lung transplantation	34
	31
Comment on “Evaluation of the safety and tolerability of intravenous undiluted levetiracetam at a pediatric institution”	31
Impact of concurrent gabapentin or pregabalin with high‐dose melphalan in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplant	30
Determination of vancomycin exposure target and individualized dosing recommendations for critically ill patients undergoing continuous renal replacement therapy	30
Reduced risk of NSAID‐Induced adverse events with concomitant use of misoprostol (MICRO study)	29
Optimal starting dosing regimen of intravenous oxytocin for labor induction based on the population kinetic‐pharmacodynamic model of uterine contraction frequency	27
Evaluation of the safety and tolerability of intravenous undiluted levetiracetam at a pediatric institution	27
Reversal of apixaban and rivaroxaban with andexanet alfa prior to invasive or surgical procedures	27
Patient safety outcomes for continuous infusion vancomycin as outpatient parenteral antimicrobial therapy	27
Consensus recommendations for the use of novel antiretrovirals in persons with HIV who are heavily treatment‐experienced and/or have multidrug‐resistant HIV‐1: Endorse	26
Response to comment on “Dosing implications for liposomal amphotericin B in pregnancy”	22
Oral fluoroquinolones and risk of aortic aneurysm or dissection: A nationwide population‐based propensity score‐matched cohort study	22
Statin‐associated muscle symptoms—A review: Individualizing the approach to optimize care	22

Biomarkers in the intensive care setting: A focus on using procalcitonin and C‐reactive protein to optimize antimicrobial duration of therapy